Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Pigment Cell Melanoma Res. 2014 Feb 21;27(3):465–478. doi: 10.1111/pcmr.12227

Figure 1. MK-2206 enhances the efficacy of carboplatin and paclitaxel in patients with BRAF-WT melanoma.

Figure 1

(A) Patients were treated with carboplatin, paclitaxel and MK-2206 in a phase I dose escalation study (NCT00848718). Patient 1 experienced a confirmed partial response. Upper 3 panels demonstrate resolution of a metastasis at the right trapezius. Lower 3 panels demonstrate resolution of a liver metastasis in the liver lobe. This response continued while on maintenance MK-2206 for 16 months. (B) Patient 2 experienced stable disease, which continued for 12 months while on maintenance MK-2206. (C) Immunohistochemistry conducted upon disease progression in the brain from patient 2 revealed PTEN (pink) expression and high levels of pAKT positivity (brown).